Transfusion Indications for Patients With Cancer

Cancer Control

Volumn 22, Issue 1, 2015, Pages 38-46

  Watkins, Thomas ^a   Surowiecka, Maria Katarzyna ^a   McCullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; HEMOGLOBIN;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD COMPONENT; BLOOD SAFETY; CANCER PATIENT; CLINICAL STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FATIGUE; GRANULOCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; IRRADIATED BLOOD COMPONENT; LEUKOCYTE; LEUKOREDUCED BLOOD COMPONENT; NONHUMAN; OUTCOME ASSESSMENT; OUTPATIENT CARE; PLASMA TRANSFUSION; REFERENCE VALUE; THERAPY EFFECT; TREATMENT INDICATION; WASHED RED BLOOD CELL; ADVERSE EFFECTS; ANEMIA; BLOOD; CHEMICALLY INDUCED; COMPLICATION; GRAFT VERSUS HOST REACTION; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANEMIA; CYTOMEGALOVIRUS INFECTIONS; ERYTHROCYTE TRANSFUSION; GRAFT VS HOST DISEASE; HEMOGLOBINS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84924756598     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481502200106     Document Type: Article

References (77)

1. Shortt J, Polizzotto MN, Waters N, et al. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. Transfusion. 2009;49(11): 2296-2303.
2. Estrin JT, Schocket L, Kregenow R, et al. A retrospective review of blood transfusions in cancer patients with anemia. Oncologist. 1999;4(4):318-324.
3. Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol. 2010;21(suppl 7):167-172.
4. Tas F, Eralp Y, Basaran M, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25(4):371-379.
5. National Institutes of Health (NIH). NIH Consensus Conference on Use of Red Cells. 3rd ed. Bethesda, MD: NIH; 1988.
6. Tas F, Eralp Y, Basaran M, et al. Anaemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2004;(suppl 1):11-26.
7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: inci­dence and treatment [Erratum in J Natl Cancer Inst. 2000;92(6):497]. J Natl Cancer Inst. 1999;91(19):1616-1634.
8. Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003;98(9):1786-1801.
9. Littlewood TJ, Bajetta E, Nortier JW, et al; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in can­cer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865-2874.
10. Cabrales P, Tsai AG, Frangos JA, et al. Oxygen delivery and consump­tion in the microcirculation after extreme hemodilution with perfluorocarbons. Am J Physiol Heart Circ Physiol. 2004;287(1)H320-H330.
11. Wilkerson DK, Rosen AL, Sehgal LR, et al. Limits of cardiac compen­sation in anemic baboons. Surgery. 1988;103(6):665-670.
12. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and met­abolic response to acute, severe isovolemic anemia. JAMA. 1998; 279:217-221.
13. Toy P, Feiner J, Viele MK, et al. Fatigue during acute isovolemic anemia in healthy, resting humans. Transfusion. 2000;40(4):457-460.
14. Grimshaw K, Sahler J, Spinelli SL, et al. New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells. Transfusion. 2011;51(4):874-880.
15. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion. 2005;45(2 suppl):33S-40S.
16. Tinmouth A, Fergusson D, Yee IC, et al; ABLE Investigators; Canadian Critical Care Trials Group. Clinical consequences of red cell storage in the critically ill. Transfusion. 2006;46(11):2014-2027.
17. Hébert PC, Wells G, Blajchman MA, et al; Transfusion Requirements in Critical Care Investigators; Canadian Critical Care Trials Group. A multi­center, randomized, controlled clinical trial of transfusion requirements in critical care [Erratum appears in N Engl J Med. 1999;340(13):1056]. N Engl J Med. 1999;340(6):409-417.
18. Vincent JL, Baron JF, Reinhart K, et al; Anemia and Blood Transfusion in Critical Care Investigators. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499-11507.
19. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med. 2004;32(1):39-52.
20. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453-2462.
21. Hébert PC; Transfusion Requirements in Critical Care. The TRICC trial: a focus on the sub-group analysis. Vox Sang. 2002;(83 suppl):387-396.
22. Lacroix J, Hébert PC, Hutchison JS, et al; TRIPICU Investigators; Ca­nadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609-1619.
23. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between post­operative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med. 1993;21(6):860-866.
24. Whitman CB, Shreay S, Gitlin M, et al. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol. 2013;8(11):1942-1951.
25. Berger MD, Gerber B, Arn K, et al. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica. 2012;97(1):116-122.
26. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49-58.
27. McCullough JJ. Complications in transfusion. In: McCullough JJ. Trans­fusion Medicine. 3rd ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2011.
28. Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49(7):1384-1394.
29. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5(1):253-259.
30. Blumberg N, Heal JM. Evidence for plasma-mediated immunomodu­lation--transfusions of plasma-rich blood components are associated with a greater risk of acquired immunodeficiency syndrome than transfusions of red blood cells alone. Transplant Proc. 1988;20(6):1138-1142.
31. Vamvakas EC, Carven JH. Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection. Arch Pathol Lab Med. 1998;122(2):145-151.
32. Blajchman MA. Immunomodulatory effects of allogenic blood transfusions: Clinical manifestations and mechanisms. Vox Sang. 1988;74(suppl 2):315.
33. Kor DJ, Van Buskirk CM, Gajic O. Red blood cell storage lesion. Bosn J Basic Med Sci. 2009;(9 suppl 1):21-27.
34. Luten M, Roerdinkholder-Stoelwinder B, Schaap NP, et al. Survival of red blood cells after transfusion: a comparison between red cells con­centrates of different storage periods. Transfusion. 2008;48(7):1478-1485.
35. Jabbour E, Kantarjian HM, Koller C, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112(5):1089-1095.
36. American Association of Blood Banks (AABB). Standards for Blood Banks and Transfusion Services. 27th ed. Bethesda, MD: AABB; 2014.
37. Ratko TA, Cummings JP, Oberman HA, et al; University Health System Consortium. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41(10):1310-1399.
38. Sharma RR, Marwaha N. Leukoreduced blood components: advan­tages and strategies for its implementation in developing countries. Asian J Transfus Sci. 2010;4(1):3-8.
39. Wenz B. Microaggregate blood filtration and the febrile transfusion reaction. A comparative study. Transfusion. 1983;23(2):95-98.
40. Blumberg N, Heal JM, Gettings KF, et al. An association between de­creased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion. 2010;50(12):2738-2744.
41. Silliman CC, Paterson AJ, Dickey WO, et al. The association of bio­logically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion. 1997;37(7):719-726.
42. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861-1869.
43. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leu­kocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598-3603.
44. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomega­lovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991;7(3):227-234.
45. Gilbert GL, Hudson IL, Hayes JJ. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet. 1989;1(8649):1228-1231.
46. Hillyer CD, Emmens RK, Zago-Novaretti M, et al. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion. 1994;34(10):929-934.
47. McCullough JJ. Clinical uses of blood components. In: McCullough JJ. Transfusion Medicine. 3rd ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2011.
48. Thaler M, Shamiss A, Orgad S, et al. The role of blood from HLA-ho­mozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989;321(1):25-28.
49. Juji T, Takahashi K, Shibata Y. HLA-homozygous donors and transfu­sion-associated graft-versus-host disease. N Engl J Med. 1990;332(14):1004-1007.
50. O’Shaughnessy DF, Atterbury C, Bolton Maggs P; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11-28.
51. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pa­thologists. Practice parameter for the use of fresh-frozen plasma, cryoprecip­itate, and platelets. JAMA. 1994;271(10):777-781.
52. Cohn CS, Stubbs J, Schwartz J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion. 2014;54(8):1927-1934.
53. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet. 2013;381(9880):1845-1854.
54. Carlson KS, DeSancho MT. Hematological issues in critically ill patients with cancer. Crit Care Clin. 2010;26(1):107-132.
55. Stanworth S. The evidence based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program. 2007;179-186.
56. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion. 2007;47(12):2180-2184.
57. Jilma-Stohlawetz P, Kursten FW, Horvath M, et al. Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded trans­fusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion. 2013;53(9):1906-1917.
58. Alavi JB, Roat RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection of acute leukemia. N Engl J Med. 1977;296(13):706-711.
59. Graw RH Jr, Herzig G, Perry S, et al. Normal granulocyte transfusion therapy. Treatment of septicemia due to gram-negative bacteria. N Engl J Med. 1972;287(8):367-371.
60. Herzig GP, Graw RG Jr. Granulocyte transfusions for bacterial infections. In: Brown EB, ed. Progress in Hematology. Vol 9. New York: Grune & Stratton; 1975:207.
61. Strauss RG. Granulocyte (neutrophil) transfusion therapy. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice. 3rd ed. Bethesda, MD: AABB; 2010.
62. Strauss RG. Therapeutic neutrophil transfusions: are controlled studies no longer appropriate? Am J Med. 1978;65(6):1001-1006.
63. Liles WC, Juang JE, Llewellyn C, et al. A comparative trial of granu­locyte-colony-stimulating factor and dexamethasone, separately and in com­bination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997;37(2):182-187.
64. Dale DC, Liles WC, Llewellyn C, et al. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. Transfusion. 1998;38(8):713-721.
65. Rutella S, Pierelli L, Piccirillo N, et al. Efficacy of granulocyte transfu­sions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy. 2003;5(1):19-30.
66. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treat­ment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95(11):3302-3309.
67. Nichols WG, Strauss R, Ambruso D, et al. G-CSF stimulated granu­locyte transfusions from unrelated community donors for severe infections during neutropenia: a phase II multi-center trial of feasibility and efficacy. Blood. 2003;102(11):978a.
68. Price TH, McCullough J, Ness P, et al. A randomized controlled trial on the efficacy of high-dose granulocyte transfusion therapy in neutropenic patients with infection. Paper presented at: 56th ASH Annual Meeting and Exposition; San Francisco, CA; December 6–9, 20https://ash.confex.com/ash/2014/webprogram/Paper68775.html. Accessed November 13, 2014.
69. McCullough J, Weiblen BJ, Fine D. Effects of storage of granulocytes on their fate in vivo. Transfusion. 1983;23(1):20-24.
70. Glasser L. Effect of storage on normal neutrophils collected by discon­tinuous-flow centrifugation leukapheresis. Blood. 1977;50(6):1145-1150.
71. McCullough J. Liquid preservation of granulocytes. Transfusion. 1989;20(2):129-137.
72. Walter RB, Lee SJ, Gardner KM, et al. Outpatient management follow­ing induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica. 2011;96(6):914-917.
73. Girmenia C, Alimena G, Latagliata R, et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hema­tologic emergency unit. Haematologica. 1999;84(9):814-819.
74. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(suppl 3):12-18.
75. Crémieux PY, Barrett B, Anderson K, et al. Cost of outpatient blood trans­fusions in cancer patients. J Clin Oncol. 2000;18(14):2755-2761.
76. Slichter J, Kaufman R, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(17):600-613.
77. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy normal apheresis platelet donors undergoing treat­ment with thrombopoietin. Blood. 2001;98(5):1346-1351.